FGF21 acts through its obligatory receptors FGFR and co-receptor β-Klotho [20], which were found to be expressed and responsive to FGF21 treatment in breast cancer cell lines (Figs. 6B and D, S2B and S2D). Here, KLB is linked to breast carcinoma.